It's true. We are recruiting. Join us!

so exciting to see our origin story in print!

TrPR’s @UCSF_AndrewPenn spoke in the Psychedelic Revival series from @PennNursing! Andrew discusses preparation for therapy, what occurs during a therapy session, and the meaning of integration. Check it out at piped.video/watch?v=TfraYldV….

@UCSF_AndrewPenn at TrPR was recently interviewed by Psychedelics Today! Check out the podcast at psychedelicstoday.com/2022/0…!

(4/4) Reconsider and Horizon also produced a feature-length documentary on psychedelics in the veteran community, which Zach is featured in. Check it out at vimeo.com/646708536! #TrPR

(1/7) TrPR is excited to announce our recent publication led by @AvronLeehe and @thebandlab, Understanding others through observed touch: neural correlates, developmental aspects, and psychopathology. Check out the study at authors.elsevier.com/a/1e2br…!

(2/2) On the podcast, Dr. Woolley discussed psilocin, the active metabolite of psilocybin, an ingredient in magic mushrooms. He explored the differences between psilocin and psilocybin, and the potential for creating psychedelic medicines.

We are hiring a clinical research coordinator to work on clinical trials of psilocybin and related compounds. Come join our team! jobs.brassring.com/TGnewUI/S…

Two major thematic change processes were identified: 1) participants reported transitioning out of habitual, evaluative modes of processing and into mindful, experiential modes of processing (from “autopilot” to “meta-aware”). Freed from their emotionally avoidant tendencies,

We focused on a sub-sample (n = 9) who had clinically significant trauma symptoms. Microphenomenological interviews were carried out 1 day after participants’ individual psilocybin sessions to elicit fine-grained descriptions of the psilocybin-assisted treatment.

Are you a clinical psychologist interested in assessments, psychedelics, and clinical trials? We are hiring for a fulltime position! sjobs.brassring.com/TGnewUI/… @thebandlab @UCSFPsychiatry @Psychedelic_Med @PsychToday @UCSF @TheBorisLab

We think the risk/benefit assessment suggests that a cautious trial, using modern trial methods focusing on appropriate ‘set’ and ‘setting’, targeted at those lowest at risk for mania in the bipolar spectrum, is needed. Feedback welcome!

We found 15 possible cases suggesting that there is potential risk for activating a manic episode, thereby warranting caution. But the evidence was sparse (e.g. only two cases involved psilocybin).

Excited to announce new preprint, "Evaluating the Risk of Psilocybin for the Treatment of Bipolar Depression: A Review of the Research Literature and Published Case Studies" led by @TrPR_Program member David Gard. medrxiv.org/content/10.1101/…